Skip to main content
Clinical Trials/NCT00897182
NCT00897182
Completed
N/A

Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray

Alliance for Clinical Trials in Oncology2 sites in 1 country96 target enrollmentMay 2008
ConditionsLeukemia

Overview

Phase
N/A
Intervention
Not specified
Conditions
Leukemia
Sponsor
Alliance for Clinical Trials in Oncology
Enrollment
96
Locations
2
Primary Endpoint
Correlation of increased or decreased expression of same transcripts with disease outcome
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment.

PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.

Detailed Description

OBJECTIVES: * To identify and validate individual genes for diagnosis of three major translocations in acute myeloid leukemia. * To correlate transcript expression data in the various translocations with age, sex, race, response to treatment, and survival and with other known mutations. OUTLINE: Blood and/or bone marrow samples previously procured from patients on CALGB-9665 are obtained from the CALGB Leukemia Tissue Bank from patients enrolled on CALGB AML treatment studies. Mononuclear cells are isolated from samples and mRNA is extracted. Gene expression profiles are analyzed via custom mRNA microarray and confirmed by quantitative real-time PCR.

Registry
clinicaltrials.gov
Start Date
May 2008
End Date
March 2014
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Correlation of increased or decreased expression of same transcripts with disease outcome

Time Frame: baseline

Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia

Time Frame: baseline

Identification of individual genes that are differentially expressed between the subtypes of AMLs

Time Frame: baseline

Correlation of the patterns of expression of the translocation-specific transcripts with age, sex, race, response to treatment, survival, and with other known mutations

Time Frame: baseline

Study Sites (2)

Loading locations...

Similar Trials